{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:55:57Z","timestamp":1781916957970,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/leu.2015.352","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T02:41:09Z","timestamp":1450665669000},"page":"1593-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials"],"prefix":"10.1038","volume":"30","author":[{"given":"P D","family":"le Coutre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D-W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N P","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Gooden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"key":"BFleu2015352_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500\u20134505.","journal-title":"Cancer Res"},{"key":"BFleu2015352_CR2","unstructured":"Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2015."},{"key":"BFleu2015352_CR3","unstructured":"Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015."},{"key":"BFleu2015352_CR4","unstructured":"Iclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals, Inc.; 2015."},{"key":"BFleu2015352_CR5","unstructured":"Tasigna (nilotinib) [prescribing information]. Stein, Switzerland: Novartis Pharma Stein AG; 2015."},{"key":"BFleu2015352_CR6","unstructured":"Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Labs; 2015."},{"key":"BFleu2015352_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310\u20131315.","journal-title":"Leukemia"},{"key":"BFleu2015352_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: S5\u2013S67.","journal-title":"J Vasc Surg"},{"key":"BFleu2015352_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329\u20131340.","journal-title":"Lancet"},{"key":"BFleu2015352_CR10","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2015352_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/028134398750003142","volume":"16","author":"JD Hooi","year":"1998","unstructured":"Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Peripheral arterial occlusive disease. Scand J Prim Health Care 1998; 16: 177\u2013182.","journal-title":"Scand J Prim Health Care"},{"issue":"6","key":"BFleu2015352_CR12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"Chatree Chai-Adisaksopha","year":"2015","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C . Major arterial events in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma 2015; e-pub ahead of print 20 October 2015; doi:10.3109\/10428194.2015.1091929.","journal-title":"Leukemia & Lymphoma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015352","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:42:35Z","timestamp":1781916155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFleu2015352"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.352","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]},"assertion":[{"value":"21 December 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PDL has received honoraria from BMS, Novartis and Pfizer, and has received research funding from Novartis. TPH has received honoraria and research funding from BMS and Novartis, and has acted in an advisory role for both companies. F-XM has served as a consultant for and has received research funding from BMS and Novartis; he has served on advisory boards for BMS, Novartis, Pfizer and Ariad. D-WK has served as a consultant for and has received honoraria and research funding from Novartis, BMS, Pfizer and Ilyang. JLS has served as a consultant for and received honoraria from BMS, Novartis and Pfizer. NPS has received research funding from BMS, Ariad and Pfizer, and serves as a DSMB member for Teva. KG and NW are employees of BMS. JEC has served as a consultant for Ariad, BMS, Novartis and Pfizer, and has received research funding from Ariad, BMS, Novartis, Pfizer and Teva.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}